PMID- 19287301 OWN - NLM STAT- MEDLINE DCOM- 20090706 LR - 20211020 IS - 1473-5571 (Electronic) IS - 0269-9370 (Print) IS - 0269-9370 (Linking) VI - 23 IP - 7 DP - 2009 Apr 27 TI - Multiple T-cell epitopes overlap positively-selected residues in the p1 spacer protein of HIV-1 gag. PG - 771-7 LID - 10.1097/QAD.0b013e32832995e0 [doi] AB - OBJECTIVES: The p1 region of HIV-1 gag contains the frameshift stem-loop, gag-pol transframe and a protease cleavage site that are crucial for viral assembly, replication and infectivity. Identifying and characterizing CD8+ epitopes that are under host immune selection in this region will help in designing effective vaccines for HIV-1. DESIGN: An approach combining bioinformatical analysis and interferon gamma enzyme-linked immunosorbent spot (ELISPOT) assays is used to identify and characterize the epitopes. Potential human leukocyte antigen (HLA)-restricted epitopes were identified by correlating the positively-selected mutations with host HLA alleles. METHODS: ELISPOT analysis with overlapping peptides was used to confirm and characterize the epitopes. RESULTS: Four positively-selected residues were significantly associated with HLA class I alleles, including HLA B*1302 (K4R, P = 0.0008 and I5L, P = 0.0108), A*7401 (S9N, P = 0.0002) and A*30 genotypes (P7S, P = 0.009), suggesting epitopes restricted by these alleles are present in this region. ELISPOT analysis with patient peripheral blood mononuclear cells (PBMCs) identified seven novel epitopes restricted by the 3 alleles. Two types of epitopes were observed in this region based on the ELISPOT responses, Type I: the positively-selected variation does not affect CD8+ T-cell responses; and Type II: the CD8+ T-cell responses are determined by the epitope variants. CONCLUSION: We identified and characterized seven novel CD8+ epitopes in the p1 spacer protein region. Classifying the effects of positively-selected variants on CD8+ T-cell responses will help in designing effective vaccines for HIV-1. FAU - Semeniuk, Christina A AU - Semeniuk CA AD - Department of Medical Microbiology, University of Manitoba, National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada. ma_luo@phac-aspc.gc.ca FAU - McKinnon, Lyle AU - McKinnon L FAU - Peters, Harold O AU - Peters HO FAU - Gubbins, Michael AU - Gubbins M FAU - Mao, Xiaojuan AU - Mao X FAU - Ball, Terry B AU - Ball TB FAU - Luo, Ma AU - Luo M FAU - Plummer, Francis A AU - Plummer FA LA - eng GR - R01 AI048373-01/AI/NIAID NIH HHS/United States GR - R01 AI056980-05/AI/NIAID NIH HHS/United States GR - R01 AI056980-04/AI/NIAID NIH HHS/United States GR - R01 AI056980-02/AI/NIAID NIH HHS/United States GR - R01 AI048373-03/AI/NIAID NIH HHS/United States GR - R01 AI056980-03/AI/NIAID NIH HHS/United States GR - R01 AI056980-01A1/AI/NIAID NIH HHS/United States GR - R01 AI048373-02/AI/NIAID NIH HHS/United States GR - R01 A149383/PHS HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - England TA - AIDS JT - AIDS (London, England) JID - 8710219 RN - 0 (Epitopes, T-Lymphocyte) RN - 0 (Gene Products, gag) RN - 0 (HLA Antigens) RN - 0 (Peptides) RN - 0 (RNA, Viral) SB - IM MH - Alleles MH - CD8-Positive T-Lymphocytes/*immunology MH - Cells, Cultured MH - Epitopes, T-Lymphocyte/genetics/*immunology MH - Female MH - Gene Products, gag/genetics/*immunology MH - HIV Infections/genetics/*immunology MH - HIV-1/*immunology MH - HLA Antigens/genetics/immunology MH - Humans MH - Immunohistochemistry MH - Peptides/genetics/immunology MH - RNA, Viral/genetics/immunology PMC - PMC2734095 MID - NIHMS99315 COIS- There are no conflicts of interest. EDAT- 2009/03/17 09:00 MHDA- 2009/07/07 09:00 PMCR- 2010/04/27 CRDT- 2009/03/17 09:00 PHST- 2009/03/17 09:00 [entrez] PHST- 2009/03/17 09:00 [pubmed] PHST- 2009/07/07 09:00 [medline] PHST- 2010/04/27 00:00 [pmc-release] AID - 10.1097/QAD.0b013e32832995e0 [doi] PST - ppublish SO - AIDS. 2009 Apr 27;23(7):771-7. doi: 10.1097/QAD.0b013e32832995e0.